NIH:OVCAR-3 nuclear extract

for NIH:OVCAR-3 nuclear extractContents

200 µg of NIH:OVCAR-3 nuclear extract at 6.52 µg/µl.

for NIH:OVCAR-3 nuclear extractBackground

NIH:OVCAR-3 nuclear extract was prepared from cell cultures of the human ovarian carcinoma NIH:OVCAR-3 cell line. The NIH:OVCAR-3 cell line was derived from malignant ascites of a 60 year old Caucasian female patient with progressive adenocarcinoma of the ovary who underwent combination chemotherapy treatment with cyclophosphamide, Adriamycin, and cisplatin. NIH:OVCAR-3 cultured cells are epithelial in morphology and are characterized by the expression of cytoplasmic androgen and estrogen specific receptor molecules. They are tumorigenic in athymic mice and have an abnormal karyotype. These cells are resistant to clinically relevant concentrations of Adriamycin, melphalan and cisplatin chemotherapies. NIH:OVCAR-3 cells are most commonly used in research as a model for ovarian carcinoma and to study the efficacy of hormone cancer therapies.

for NIH:OVCAR-3 nuclear extractApplication Notes

NIH:OVCAR-3 nuclear extract is specifically recommended for ovarian cancer and hormone therapy studies.

for NIH:OVCAR-3 nuclear extractExtract Origin

Human ovary adenocarcinoma

for NIH:OVCAR-3 nuclear extractExtract Composition

NIH:OVCAR-3 nuclear extract is supplied in Dilution Buffer (20 mM Hepes (pH 7.9), 100 mM KCl, 1 mM MgCl₂, 20% glycerol, 0.5 mM PMSF and 0.5 mM DTT).

for NIH:OVCAR-3 nuclear extractQuality Control

Extracts have been quality control tested by Western blot and the Electrophoretic Mobility Shift Assay (EMSA).

for NIH:OVCAR-3 nuclear extractStorage

To ensure stability, extracts should be stored at -80°C.

We recommend aliquoting the extracts into single-use fractions and then storing them at -80°C. This eliminates repeated freeze/thaw cycles.

for NIH:OVCAR-3 nuclear extractGuarantee

This product is guaranteed for 6 months from date of receipt.

This product is for research use only and is not for use in diagnostic procedures.